SUBSCRIBE: Print / Digital / eNewsletter
Rho kinase inhibitors—the newest drugs introduced for treating glaucoma—"get to the heart of the matter” by targeting specific glaucomatous abnormalities, such as trabecular meshwork outflow, said Yvonne Ou, MD.
This article was reviewed by Leslie Jones, MD
Richard Adler, MD, shares the methods his practice has used to implement intense pulsed light (IPL) therapy into their patient base, while attending the 2019 American Academy of Ophthalmology's annual meeting in San Francisco.
Anti-VEGF injections are associated with acute IOP spikes and chronic IOP rise in patients, and these increases in IOP need to be acknowledged and managed, according to Matthew Schlenker MD, MSc, FRCPC.
This article was reviewed by Prof Gus Gazzard, FRCOpthMA, MBBCHIR, MD
This article was reviewed by Janet B. Serle, MD
This article was reviewed by Davinder S. Grover, MD, MPH
The future of glaucoma will likely not resemble the current state of management of the disease, with numerous advances on the horizon, according to Harry Quigley MD, the A.
This article was reviewed by Janet B. Serle, MD
Steven Vold, MD, founder and CEO of Vold Vision in Northwest Arkansas, shares how his practice uses intense pulsed light (IPL) therapy to treat dry eye disease (DED) in
With a goal of becoming an innovator in minimally invasive glaucoma surgery (MIGS) and procedure-based dry eye treatments, Sight Sciences earlier this yea
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
